Iradimed Corp. (IRMD) Tops Q2 EPS by 3c; Raises Outlook

Iradimed Corp. (NASDAQ: IRMD) reported Q2 EPS of $0.24, $0.03 better than the analyst estimate of $0.21. Revenue for the quarter came in at $9.9 million versus the consensus estimate of $9.6 million.

GUIDANCE:

Iradimed Corp. sees Q3 2016 EPS of $0.23-$0.24, versus the consensus of $0.22. Iradimed Corp. sees Q3 2016 revenue of $9-10 million, versus the consensus of $9.9 million.

Iradimed Corp. sees FY2016 EPS of $0.91-$0.93, versus prior guidance of $0.88-$0.90 and the consensus of $0.89. Iradimed Corp. sees FY2016 revenue of $39-40 million, versus the consensus of $39.15 million.

For earnings history and earnings-related data on Iradimed Corp. (IRMD) click here.

You May Also Be Interested In

• Gilead Sciences (GILD) Misses Q1 EPS by 288c
• The First Of Long Island (FLIC) Misses Q1 EPS by 3c
• Minerals Technologies (MTX) Tops Q1 EPS by 16c